MedTrace Logo

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

NCT01930175 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2021-10-08

Study results available
· View outcomes & findings →

Summary

The study evaluated the efficacy, safety and pharmacokinetics of VAY736 in the treatment of patients with pemphigus vulagaris (PV).

Conditions

  • Pemphigus Vulgaris

Interventions

DRUG

VAY736

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-18
Primary Completion
2019-09-25
Completion
2019-09-25
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Bulgaria
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01930175 on ClinicalTrials.gov